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Abstract
Frontotemporal lobar degeneration with neuronal inclusions of the TAR DNA-binding protein 43 
(FTLD-TDP) represents the most common pathological subtype of FTLD. We established the 
international FTLD-TDP whole genome sequencing consortium to thoroughly characterize the 
known genetic causes of FTLD-TDP and identify novel genetic risk factors. Through the study of 
1,131 unrelated Caucasian patients, we estimated that C9orf72 repeat expansions and GRN loss-
of-function mutations account for 25.5% and 13.9% of FTLD-TDP patients, respectively. 
Mutations in TBK1 (1.5%) and other known FTLD genes (1.4%) were rare, and the disease in 
57.7% of FTLD-TDP patients was unexplained by the known FTLD genes. To unravel the 
contribution of common genetic factors to the FTLD-TDP etiology in these patients, we conducted 
a two-stage association study comprising the analysis of whole-genome sequencing data from 517 
FTLD-TDP patients and 838 controls, followed by targeted genotyping of the most associated 
genomic loci in 119 additional FTLD-TDP patients and 1653 controls. We identified three 
genome-wide significant FTLD-TDP risk loci: one new locus at chromosome 7q36 within the 
DPP6 gene led by rs118113626 (pvalue=4.82e-08, OR=2.12), and two known loci: UNC13A, led 
by rs1297319 (pvalue=1.27e-08, OR=1.50) and HLA-DQA2 led by rs17219281 (pvalue=3.22e-08, 
OR=1.98). While HLA represents a locus previously implicated in clinical FTLD and related 
neurodegenerative disorders, the association signal in our study is independent from previously 
reported associations. Through inspection of our whole genome sequence data for genes with an 
excess of rare loss-of-function variants in FTLD-TDP patients (n≥3) as compared to controls 
(n=0), we further discovered a possible role for genes functioning within the TBK1-related 
immune pathway (e.g. DHX58, TRIM21, IRF7) in the genetic etiology of FTLD-TDP. Together, 
our study based on the largest cohort of unrelated FTLD-TDP patients assembled to date provides 
a comprehensive view of the genetic landscape of FTLD-TDP, nominates novel FTLD-TDP risk 
loci, and strongly implicates the immune pathway in FTLD-TDP pathogenesis.
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Introduction
Frontotemporal lobar degeneration (FTLD) is one of the leading causes of dementia in 
individuals younger than 65 years but can also affect individuals later in life. In the past two 
decades, a number of monogenic causes and genetic risk factors of FTLD have been 
described. Mutations in the genes encoding microtubule associate protein tau (MAPT) and 
progranulin (GRN), and repeat expansions in the chromosome 9 open reading frame 72 
(C9orf72) gene were identified as the most common genetic causes of FTLD [37,4,16]; 
however, the majority of patients remain genetically unexplained. FTLD is an umbrella term 
for a highly heterogeneous group of clinical syndromes that result from selective 
dysfunction and typically atrophy of the frontal and temporal lobes. The predominant 
clinical presentations of FTLD are behavior and language dysfunction resulting in 
behavioral variant (bvFTD) [74], semantic variant of primary progressive aphasia (svPPA) or 
agrammatic variant of primary progressive aphasia (agPPA) [31]; however, related clinical 
syndromes such as frontotemporal dementia with motor neuron disease (FTD-MND), 
progressive supranuclear palsy (PSP) syndrome, and corticobasal syndrome (CBS) can 
occur. Patients with FTLD may further present with psychiatric symptoms and conditions 
such as compulsive behavior, mood disorders, and schizophrenia [101]. FTLD 
neuropathological studies have also revealed heterogeneity and pathological classification is 
now defined by the main component of the protein aggregates in a patient’s brain at post 
mortem examination. FTLD with neuronal and cytoplasmic aggregates of the DNA and 
RNA binding protein TDP-43 (FTLD-TDP) is most common and based on the distribution 
of the neuronal cytoplasmic TDP-43-positive inclusions and dystrophic neurites in the 
cortical layers at least five distinct FTLD-TDP pathological subtypes (A-E) are described 
[54,44]. Interestingly, while the nature of the underlying FTLD pathology is challenging to 
predict in most clinically diagnosed FTLD patients, mutations in GRN invariably lead to 
FTLD-TDP type A while repeat expansions in C9orf72 are mainly associated with FTLD-
TDP type B [53]. In contrast, patients with mutations in MAPT accumulate pathological tau 
proteins (FTLD-tau) and do not have FTLD-TDP pathology [9]. These correlations between 
specific gene mutations and pathology subgroups provides validation for the pathological 
classification system and suggests that, at least in part, distinct molecular pathways could 
contribute to disease in the various FTLD pathological subtypes. Consequently, genetic 
studies focused on large clinical cohorts may have reduced power due to undesirable 
heterogeneity and analysis of specific FTLD pathological subtypes may be beneficial. 
Indeed, the inclusion of clinical patients in genome-wide association study (GWAS) has 
been successful by identifying one genome-wide significant association signal for FTLD at 
the HLA locus on chromosome 6 but required more than 2,000 FTLD patients and 4,000 
controls [26]. On the contrary, the use of a much smaller cohort of pathologically confirmed 
FTLD-TDP patients identified TMEM106B as a genetic risk factor [85]. The latter study, 
however, was performed more than 8 years ago, only focused on common genetic variants, 
and included a significant number of patients with pathogenic GRN mutations and repeat 
expansions in C9orf72, underscoring the need for additional studies.
Here we present the results of our newly established International FTLD-TDP whole 
genome sequencing (WGS) consortium, in which we identified more than 1,150 unrelated 
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pathologically confirmed FTLD-TDP patients from 23 participating sites. Genome-wide 
association studies in 517 Caucasian FTLD-TDP patients without mutations in the known 
genes and 838 controls identified common risk variants at one novel (DPP6) and two known 
loci (UNC13A and HLA-DQA2) and suggests that rare damaging variants in the TBK1-
related innate immune pathway are enriched in FTLD-TDP patients as compared to controls. 
These findings extend the genetic landscape of FTLD-TDP and further highlight immune 
dysfunction as a potential contributing factor in the development of FTLD-TDP.
Methods
Study subjects and basic genetic and pathological characterization
International FTLD-TDP whole genome sequencing (WGS) Consortium.—To 
identify novel genetic factors implicated in FTLD-TDP, we established the International 
FTLD-TDP WGS Consortium. Previously ascertained FTLD-TDP patients from 23 
European, North American and Australian participating sites were included, one patient per 
family (Table 1). The pathological diagnosis of FTLD-TDP was considered sufficient for 
inclusion, irrespective of the clinical diagnosis of the patient. Patients diagnosed with FTLD-
TDP and concomitant signs of motor neuron disease were also included. The availability of 
DNA for basic genetic characterization was considered an additional inclusion criterion such 
that the presence of a C9orf72 expansion could be determined in all patients, mutations in 
GRN could be determined in all FTLD-TDP type A patients and VCP could be screened in 
all FTLD-TDP type D patients. For those patients in which mutation status was not yet 
available at the start of the study, C9orf72 repeat expansions were analyzed using our 
previously reported two-step protocol and Sanger sequencing was used for GRN and VCP 
mutation screening [20,4,96]. Information on the presence of known disease mutations in 
other neurodegenerative disease genes within the cohort was requested from all participating 
sites but not all patients were systematically screened. A total of 1,134 Caucasian and 20 
non-Caucasian FTLD-TDP patients were identified.
Discovery cohort.—The discovery stage included 554 genetically unexplained self-
declared Caucasian FTLD-TDP patients with sufficient DNA quality and quantity available 
for WGS. Participating sites were required to provide the FTLD-TDP pathological subtyping 
for each patient according to the harmonized classification system or had to provide 
unstained fixed tissue slides such that phospho-TDP-43 immunostaining could be performed 
as part of this study. WGS was also available for 982 control individuals from the Mayo 
Clinic Biobank which is a convenience population collected at Mayo Clinic with detailed 
clinical records on each participant (Table 2) [67]. After quality control measures (see 
below), 517 FTLD-TDP patients and 838 controls were included in the genetic analyses.
Replication cohort.—For the replication stage, a total of 119 FTLD-TDP patients were 
available, including both newly ascertained FTLD-TDP patients and patient samples that 
failed quality control measures at the discovery stage, e.g. low coverage and low call rate 
(Table 2). FTLD-TDP patient samples from the discovery stage that failed quality control 
measures due to contamination, race, sex error or duplicates were not selected for the 
replication cohort. FTLD-TDP patients known to be related to individuals included in the 
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discovery cohort were excluded. Similar to the discovery cohort, all patients were negative 
for C9orf72 repeat expansions and FTLD-TDP type A patients were negative for mutations 
in GRN. A total of 1,653 controls including a set of 249 pathologically confirmed normal 
controls as well as 1,404 clinical controls free of neurodegenerative disorder were used as 
the control cohort. Patients and controls were all reported Caucasian and originated from 
multiple sites (Table 2, suppl. table 2 Online Resource 1).
WGS discovery cohort
Whole blood or brain-derived DNA from 499 of the 554 unrelated FTLD-TDP patients from 
the discovery cohort and 982 individuals from the Mayo Clinic Biobank Study were whole 
genome sequenced at HudsonAlpha. Approximately 1000ng DNA from each sample was 
sheared on a Covaris LE220 focused-ultrasonicator (Woburn, MA, USA) with a target yield 
of 350bp fragment size. Following sonication, the fragmented DNA was taken into standard 
library preparation protocol using NEBNext® DNA Library Prep Master Mix Set for 
Illumina® (New England BioLabs Inc., Ipswich, MA, USA) with slight modifications. The 
post-ligated samples were individually barcoded with unique in-house primers and amplified 
through 6 cycles of PCR using KAPA HiFi HotStart Ready Mix (Kapa Biosystems, Inc., 
Woburn, MA, USA). Concentration of the libraries was assessed by Qubit® 2.0 
Fluorometer, and the quality of the libraries was estimated by utilizing a DNA 5K chip on a 
Caliper GX, respectively. Accurate quantification was determined using the qPCR-based 
KAPA Biosystems Library Quantification kit (Kapa Biosystems, Inc., Woburn, MA, USA). 
Each sample was sequenced on one lane of Illumina’s HiSeq X instrument using v2 flow 
cells and reagents to target 30X genomic coverage. Fastq files previously generated on an 
Illumina HiSeq X for 55 FTLD-TDP patients were obtained from 3 sites: UCSF (n=36) [30], 
DZNE (n=14) and NSW (n=5) leading to a total of 554 FTLD patients whole genome 
sequenced.
For all FTLD-TDP patients and controls fastq files were transferred to Mayo Clinic and 
processed through the Mayo Genome GPS v4.0 pipeline in batches of up to 75 samples. 
Briefly, reads were mapped to the human reference sequence (GRCh38 build) using the 
Burrows–Wheeler Aligner, and local realignment around indels was performed using the 
Genome Analysis Toolkit (GATK) [46,56]. Variant calling was performed using GATK 
HaplotypeCaller followed by variant recalibration (VQSR) according to the GATK best 
practices recommendations [22,86].
WGS data quality assessment
Sample level quality control.—Samples with less than 30X coverage in more than 50% 
of the genome (n=17 patients, n=41 controls), call rate below 85% (n=1 patient, n=0 
controls), sex error (n=4 patients, n=2 controls) or contamination defined by a FREEMIX 
score above 0.03 (n=6 patients, n=4 controls) were removed. Non-Caucasian samples (n=6 
patients, n=3 controls) were also removed. At this step, joint genotyping on all samples was 
performed, a final relatedness measurement was calculated using PREST [57], and duplicate 
samples (n=3 patients, n=0 control) as well as related ones (n=0 patient, n=25 controls) were 
removed. In total, 517 pathologically confirmed FTLD-TDP samples and 907 controls 
passed all quality control measures. After removing 69 controls with a possible clinical 
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diagnosis or family history of a neurodegenerative disorder as per clinical chart review, 517 
FTLD-TDP patients and 838 controls were included in genetic association analyses.
Variant level quality control.—Genotype calls with GQ<10 and/or depth (DP) <10 were 
set to missing, and variants with ED > 4 were removed from all subsequent analyses. For all 
analyses, only variants that pass VQSR and with a call rate >95% were considered unless 
otherwise specified. The transition/transversion ratio for this final variant call set is 2.04. 
Functional annotation of variants was performed using ANNOVAR (version2016Feb01) 
[94]. Genotypes generated at the discovery phase for the top single nucleotide 
polymorphisms (SNPs, rs118113626, rs17219281 and rs12973192) were validated by 
independent Taqman assays (C_11514504_10 for rs12973192 – custom assays were 
designed for rs118113626 and rs17219281) on 466 FTLD-TDP patients and 837 controls 
included in the discovery phase with DNA available. All genotypes from the whole genome 
sequencing phase were confirmed by an orthogonal method. In addition, rs4726389 and 
rs118113626 were Sanger sequenced in a subset of 46 FTLD-TDP patients and 46 controls 
from the discovery phase and all genotypes were confirmed (primers available upon 
request). Rare loss of function variants (frameshift insertion/deletion/block substitution, 
stopgain, stoploss and splicing single nucleotide variants - SNVs) in TBK1, TRIM21, 
DHX58, IRF7, IRF8, IRF3 and NOD2 were confirmed by Sanger sequencing (primers 
available upon request).
Genotyping replication cohort
13 suggestive loci (p<1e-05) were nominated for follow-up in the replication stage. For all 
suggestive loci, the lead variant and/or one proxy were included in a multiplex MassArray 
design (Agena Bioscience, San Diego, CA, USA) leading to a maximum of two variants per 
loci at the design stage. Two loci failed the design (rs148048968, rs3952538). Twenty 
nanograms of DNA as measured by spectrophotometer (Nanodrop; Wilmington, DE, USA) 
were used for genotyping on the MassArray iPLEX system (Agena Bioscience, San Diego, 
CA, USA) following the manufacturer’s protocol. Variants with a call rate <95% or failing 
Hardy-Weinberg equilibrium in controls (p<0.05) were subsequently removed from the 
analysis (one variant, rs9818987). Both genome-wide significant DPP6 variants and one 
variant at each other locus (either the lead variant or a proxy) were retained for statistical 
analysis resulting in a total of 11 loci. Individuals with a genotyping rate <95% were 
removed from the analysis.
RNAseq analysis
RNA from frontal cortex tissue of 44 FTLD-TDP patients without known gene mutations 
and 24 pathologically confirmed normal controls was extracted using the RNeasy Plus mini 
kit (Qiagen, Venlo, Netherlands). RNA quality and quantity were determined with an 
Agilent 2100 Bioanalyzer using the RNA Nano Chip (Agilent Technologies). Only high-
quality RNA samples were included (median RIN=9.3, IQR=8.8–9.8). Library preparation 
was performed using Illumina TruSeq mRNA v2 prep and sequenced at 10 samples/lane as 
paired-end 101 base pair reads on the HiSeq 4000 (Illumina, San Diego, CA). Raw RNAseq 
reads were aligned to the human reference genome (GRCh38) using the spliced transcripts 
alignment to a reference (STAR, v2.5.2b) [25]. Library quality was assessed using the 
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RSeQC (v3.0.0) package [95]. Gene-level expression was quantified using the featureCounts 
command in the Subread package (v1.5.1) [49]. An in-house R pipeline was used to obtain 
differentially expressed genes. Briefly, the R pipeline includes conditional quantile 
normalization (CQN), principal component (PC) analysis, source of variation (SOV) 
analysis, and differential expression analysis of genes. Differential expression analysis was 
performed using multivariable linear regression models adjusted for potential confounders. 
A Benjamini–Hochberg FDR correction was used for multiple testing. Analyses were 
performed with or without the incorporation of surrogate markers for five major cell types as 
covariates: neurons (ENO2), microglia (CD68), astrocytes (GFAP), oligodendrocytes 
(OLIG2), and endothelial cells (CD34), as described elsewhere [32,18,3]. All analyses also 
included the following covariates: RNA integrity number (RIN), sex, age, and plate.
DPP6 mRNA expression analyses
mRNA expression analysis of DPP6 was conducted in one FTLD-TDP patient carrying a 
possible LOF variant and two neuropathologically normal controls in which DPP6 LOF 
variants were excluded. RNA was extracted and quality was measured as described before. 
All RNA obtained had a RIN>8 and was subsequently reverse transcribed using the 
Superscript III system (Life Technologies, Carlsbad, CA, USA). Quantitative real-time PCR 
was performed in quadruplicate for each sample on an ABI7900 PCR system (Applied 
Biosystems, Foster City, CA, USA), using TaqMan gene expression assays (Life 
Technologies, Carlsbad, CA, USA) and following the manufacturer’s recommendations. 
DPP6 transcripts were measured using the probe Hs00736294_m1 for all DPP6 transcripts 
from Invitrogen (Carlsbad, CA, USA). MAP2 (probe Hs00258900_m1) and GAPDH (probe 
Hs02758991_g1) were used as reference genes. Results were analyzed using SDS software 
version 2.2 (Life Technologies, Carlsbad, CA, USA). DPP6 transcript levels were assessed 
using the ΔΔCt method normalized by the geometric mean of MAP2 and GAPDH 
transcripts to account for both total cell number and the contribution of neuronal cells 
specifically. In addition, after reverse transcription, a cDNA fragment containing the splice 
site mutation as well as two known common variants (rs2293353 and rs2230064) was 
amplified by PCR and Sanger sequenced from the patient carrying the potential LOF DPP6 
variant and one healthy control. Presence of heterozygous status for rs2293353 and 
rs2230064 was confirmed at the gDNA level by Sanger sequencing (primers are available 
upon request).
Statistical analyses
Age at onset, death and survival after onset analyses.—Distribution of ages at 
onset, ages at death and survival after onset were compared between patients included in the 
discovery phase with an FTLD-TDP subtype A, B and C by using a Kruskal-Wallis test 
followed by a post-hoc Dunn’s test. Pvalues of the Dunn’s test are provided after Bonferroni 
correction.
Generation of principal components.—Prior to running genetic association analyses, 
PC analysis was performed using a subset of variants meeting the following criteria: minor 
allele frequency (MAF) >5% and full sample Hardy Weinberg Equilibrium (HWE) p>1e-5. 
For the PC analysis and common variant genome-wide association analyses, multi-allelic 
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variants were split into multiple variables (i.e. rows in the genotype dataset), where each 
variable/row represents the count of a specific alternate allele with samples carrying other 
alternate alleles being set to missing. Influential regions such as the HLA region were 
removed, and SNPs were pruned by LD with r2 threshold of 0.1 prior to PC analysis. This 
analysis identified 4 PCs that were significantly associated with patient control status, which 
were subsequently used as covariates in all genetic association analyses.
SNP-level analysis of common variants.—For the common variant GWAS, SNPs 
with MAF>0.01 in patients or controls and HWE p>1e-6 in controls were analyzed. Multi-
allelic markers were encoded as described above. In addition, since WGS of FTLD-TDP 
patients was performed at HudsonAlpha in 5 batches, a test was performed to identify SNPs 
with significant differences in genotype distributions between sequencing batches, and SNPs 
showing evidence of batch effects (p<0.05) were removed.
For all remaining variants, association of genotypes with the patient/control status was 
assessed using logistic regression with allele dosage as the predictor assuming log-additive 
allele effects. Sex and the first four PCs were included as covariates in the models. 
Following the primary analysis comparing SNP genotypes between all FTLD-TDP patients 
and controls, exploratory analyses within pathological FTLD-TDP strata were performed to 
evaluate SNP association with FTLD-TDP type A, type B and type C. The SNP-level 
analyses were performed using PLINK v1.90b6.5 64-bit (13 Sep 2018) [72]. Meta-analyses 
of the discovery and replication results were performed under a fixed effects model. The I2 
heterogeneity statistics is provided to evaluate the degree of heterogeneity of the effects in 
the discovery and replication stages.
Gene-level analysis of rare variants: Association of rare variants with the patient/control 
status was assessed using an unweighted burden test implemented using the SKAT_1.2.1 R 
package [97]. For the rare variant analyses multi-allelic markers were split into multiple 
“variants” or variables (i.e. multiple rows in the genotype file), with a particular alternate 
allele being counted for each variable, and with genotypes corresponding to other alternate 
alleles being set to 0. Thus, each row in the data file represents a count of a particular 
alternate allele and is only missing when no alleles were called. Only VQSR pass variants 
with call rate >90%, ED≤4, and MAF<0.01 in either patients or controls were included in 
these rare-variant gene-based analyses. Two sets of analyses were performed: The first 
included only frameshift (insertion/deletion/block substitution), stopgain, stoploss and 
splicing SNVs (jointly defined as loss-of-function (LOF) variants), while the second 
included all variants captured in the first analysis as well as non-synonymous SNVs and 
non-frameshift indels or block substitutions that were predicted to be probably damaging by 
Polyphen 2 and deleterious by SIFT [1,61]. Sex and the first four PCs were used as 
covariates in the model. As with the common SNP GWAS, analyses were performed with all 
FTLD-TDP patients, followed by exploratory analyses in pathological FTLD-TDP strata. 
Because adjustment for PCs in extremely rare variants might lead to spurious associations 
due to the rarity of mutation carriers, pvalues are provided with and without the 
incorporation of PCs in the models. Finally, for the rare variant analysis in DPP6 we 
included all missense variants and LOF variants passing quality control and with a 
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MAF<0.01 in either patients or controls and performed a SKAT test as implemented in the 
SKAT R package allowing bidirectionality of the effect of variants. The association was 
assessed with and without adjustment for the associated common SNPs in DPP6 (rs4726389 
and rs118113626). Exome-wide significance was defined as a pvalue<2.5e-06 (Bonferroni 
correction for 20,000 genes).
Gene prioritization
All genes with nominal significance identified through burden test with rare LOF mutations 
or coding variants predicted to be pathogenic by Polyphen2 and SIFT prediction software 
were subject to a gene ontology (biological processing) and KEGG pathway analysis using 
Webgestalt [102,93]. In addition, for all genes where at least 3 such variants were identified 
in FTLD-TDP patients and none in controls, a similarity analysis using the ToppGene 
database was performed [10]. As training set, we used the following genes: C9orf72, GRN, 
TBK1, OPTN, VCP, TARDBP, CHCHD10, SQSTM1, UBQLN2, hnRNPA1, hnRNPA2B1, 
CSF1R, FUS, CHMP2B, LRRK2 and TIA1. The default training parameters were used as 
follows: Gene ontology molecular function, biological process and cellular component; 
human and mouse phenotype; pathway (BIOCYC, KEGG, Pathway Interaction Database, 
REACTOME, GenMAPP, MSigDB C2 BIOCARTA (v6.0), PantherDB, Panther Ontology, 
SMPDB); PubMed and Disease. For each gene false discovery rate qvalues are reported.
Results
Frequency of known gene mutations within the International FTLD-TDP WGS Consortium
Through collaborative efforts across North America, Europe and Australia, we established 
the International FTLD-TDP WGS Consortium and identified 1,154 unrelated patients with 
a pathologically confirmed diagnosis of FTLD-TDP and a source of DNA available for basic 
genetic characterization (Table 1). Analyses of common known genetic causes of FTLD-
TDP revealed C9orf72 repeat expansions in 25.5% and GRN mutations in 13.8% of 
Caucasian patients, together explaining the disease in nearly 40% of our Caucasian FTLD-
TDP cohort. TBK1 and other rare gene mutations accounted for an additional 0.9% and 
1.2% of Caucasian patients, respectively, with the caveat that these genes were only 
analyzed in a subset of patients. In the non-Caucasian population, GRN mutations were the 
most frequent, explaining 20.0% of patients, compared to only 10.0% of FTLD-TDP 
patients with the C9orf72 repeat expansion.
To identify genetic factors contributing to the disease in Caucasian FTLD-TDP patients 
without a known gene mutation, we next performed WGS on 554 patients with sufficient 
DNA quality and quantity available. A total of 982 individuals from the Mayo Clinic 
Biobank Study underwent WGS at the same time (Table 2). For each patient, pathological 
FTLD-TDP subtyping was available based on TDP-43 immunostaining. FTLD-TDP type B 
was most common (n=199), followed by FTLD-TDP type A (n=171) and C (n=161). FTLD-
TDP type D (VCP gene negative) was observed in 4 patients and in 19 patients the subtyping 
was ambiguous. The distribution of ages at onset, ages at death and survival after onset were 
significantly different between the FTLD-TDP subtypes (Kruskal-Wallis test 
pvalueage at onset=6.2e-10; pvalueage at death=2.0e-14; pvaluesurvival after onset < 2.2e-16, Figure 
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1, Table 3). In particular, FTLD-TDP type A patients were the oldest at onset with a median 
age of 68.0 years (IQRTDPA=59.0–75.8), which was significantly different from FTLD-TDP 
type B and type C patients (AAOTDPB=62.0, IQRTDPB=55.0–69.0, pvalue=5.3e-07; 
AAOTDPC=60.8, IQRTDPC=55.8–65.4, pvalue=4.9e-09). FTLD-TDP type B patients died 
significantly younger (AADTDPB=67.0, IQRTDPB=60.0–74.0) as compared to FTLD-TDP 
type A patients (AADTDPA=78.0, IQRTDPA=67.0–85.0, pvalue=8.4e-15) and FTLD-TDP 
type C patients (AAOTDPC=72.0, IQRTDPC=66.7–76.0, pvalue=4.9e-05) and FTLD-TDP 
type C patients had the longest survival after onset with a median survival of 11.0 years 
(IQRTDPC=8.1–13.2) as compared to 7.2 years (IQRTDPA=4.0–11.0, pvalue=9.0e-08) in 
FTLD-TDP type A and 3.8 years (IQRTDPB=2.0–6.0, pvalue=2.7e-35) in FTLD-TDP type 
B.
After quality control, 517 FTLD-TDP patients and 838 controls free of neurodegenerative 
disorders were retained and included in genetic studies. An average sequencing depth of 
40X was achieved for both patients and controls that passed quality controls. To further 
characterize the presence of known gene mutations within our FTLD-TDP cohort, we first 
queried the whole-genome dataset for variants observed in FTLD-TDP patients with a minor 
allele frequency <0.1% in the EXAC database and absent from our control dataset in the 
following genes: GRN, TBK1, OPTN, VCP, TARDBP, CHCHD10, SQSTM1, UBQLN2, 
hnRNPA1, hnRNPA2B1, CSF1R, FUS, CHMP2B, LRRK2, and TIA1. This led to the 
identification of LOF mutations in TBK1 in 7 additional FTLD-TDP patients (pvalueburden= 
5.15e-03). Together with the 10 TBK1 carriers that were already known at the initiation of 
the International FTLD-TDP WGS Consortium, this brings the total to 17 TBK1 mutation 
carriers versus none in controls. We also detected two variants in OPTN, one variant in GRN 
and one variant in CHMP2B, each of which was defined by the American College of 
Medical Genetics and Genomics (ACMG) as pathogenic (Table 4, Online Resource 2). Of 
note, the pathogenic GRN variant was a splicing variant c.708+6_+9delTGAG which had 
been missed due to its position near the 3’ splice site of exon 7.[6] By adding these newly 
identified pathogenic variants to the overall cohort, C9orf72 repeat expansions explained 
25.5% of our Caucasian FTLD-TDP cohort, 13.9% of the patients carried a GRN mutation, 
1.5% carried a TBK1 mutation and 1.4% carried a mutation in another known disease gene 
(suppl. table 1 Online Resource 1). Conversely, 57.7% of Caucasian FTLD-TDP patients 
were not explained by mutations in the known genes.
Identification of common FTLD-TDP genetic risk factors
To identify novel common genetic risk factors for FTLD-TDP, we next performed single 
variant genome-wide association for the 7,083,292 common variants (MAF>0.01 in either 
FTLD-TDP patients or controls) that passed quality control in the 517 FTLD-TDP patients 
and 838 controls. Genomic inflation was moderate (λ=1.05). Logistic regression adjusting 
for sex and first four PCs identified one genome-wide significant locus at chromosome 
7q36.2. The signal was driven by two variants: rs4726389 and rs118113626 located in the 
DPP6 intron 1 region (Table 5, Figure 2; p=4.63e-08, OR=2.453; p=4.88e-08, OR=2.481). 
Both variants at the DPP6 locus were in linkage disequilibrium (r2=0.77 and D’=0.88) and 
conditional analysis on rs4726389 abolished the significant association of rs118113626. No 
additional common variants were detected with an r2>0.5 at the 7q36.2 locus. Variants 
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rs4726389 and rs118113626 were not reported as expression quantitative trait loci (eQTL) in 
public databases and rs4726389 had a Regulomedb score of 6 suggesting minor effect on 
regulatory elements. Moreover, analysis of DPP6 mRNA expression in a custom RNAseq 
dataset of frontal cortex tissue samples of FTLD-TDP patients (n=68) did not show an effect 
of rs4726389 on DPP6 mRNA expression (pvalue=0.88 after FDR correction, fold change = 
1.01; Figure 2). Compared to control tissue samples, we did observe a decrease in DPP6 
mRNA expression in FTLD-TDP patients; however, after correction for cell type 
composition, this association was no longer significant (pvalue=0.89 after FDR correction, 
Figure 2). By investigating the presence of rare variants in DPP6 in our dataset, we further 
identified one LOF variant in our FTLD-TDP patients: the splice variant c.1345+1G>T 
(cDNA positions is provided according to NM_130797), whereas LOF variants were not 
observed in our control cohort. The LOF variant reduced cortex mRNA expression of DPP6 
by 41% and cDNA sequencing suggested degradation of the mutant allele by nonsense 
mediated decay (suppl. figure 1 Online Resource 1). We also identified 26 DPP6 non-
synonymous variants with a MAF less than 1% in either patients or controls. A SKAT test 
including the two LOF variants and the 26 missense variants resulted in a trend towards 
association of DPP6 rare damaging variants with FTLD-TDP but failed to reach significance 
(pvalue=0.07). After adjustment for the top common SNPs this result did not change 
substantially suggesting the DPP6 common variant and rare variant associations with FTLD-
TDP are independent from one another.
In addition to the DPP6 locus, 12 suggestive loci with a pvalue <1e-05 were identified 
(Table 5). Of the 13 loci, 11 were successfully followed-up in an independent replication 
cohort of newly ascertained FTLD-TDP patients (n=119) and controls (249 pathologically 
confirmed normal controls and 1,404 clinical controls). A meta-analysis combining the 
discovery and the replication stages resulted in three loci with genome-wide significance 
(Table 5). Rs118113626 at the DPP6 locus remained genome-wide significant despite some 
heterogeneity between the two stages. The strongest signal however was found at 
chromosome 19p13.11 at the UNC13A locus, with top SNP rs12973192 (pvalue=1.27e-08, 
OR=1.50) followed by rs17219281 on chromosome 6p21.32 at the HLA-DQA2 locus 
(pvalue= 3.22e-08, OR=1.98). According to the GTex database, rs17219281 is reported as 
an eQTL for HLA-DQB2 and HLA-DQA2 with the most significant association found with 
their expression in cortex for HLA-DQB2 (pvalue=6.2e-07) and in amygdala for HLA-
DQA2 (pvalue=2.7e-03); the rare allele consistently increasing HLA-DQB2 and HLA-
DQA2 gene expression.
In exploratory analysis, we next performed genome-wide association analyses within each 
FTLD-TDP strata (FTLD-TDP type A, B and C). Loci which showed suggestive association 
(pvalue <1e-05) in at least one of the strata are shown in suppl. table 3 (Online Resource 1). 
Interestingly, rs12973192 in UNC13A reached genome-wide significance within FTLD-
TDP type B (pvalue=4.67e-08, OR=1.95), with virtually no association of rs12973192 with 
FTLD-TDP type A and C (pvalueTDPA=1.90e-02, OR=1.35; pvalueTDPC=4.94e-01, 
OR=1.10). In contrast, within FTLP-TDP type A patients, the GRN locus on chromosome 
17 showed most significance. While the additive model resulted in a suggestive pvalue of 
1.69e-07 at this locus in FTLD-TDP type A (rs708384), further investigation under different 
modes of inheritance, showed a much stronger and genome-wide significant signal using a 
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recessive model with most significance at rs5848 located in the 3’untranslated region of 
GRN (pvalue=4.99e-12; OR=5.16). No genome-wide significant associations were found in 
FTLD-TDP type C.
Finally, KEGG pathway enrichment analysis including all suggestive loci in either the 
overall FTLD-TDP cohort or pathological strata (suppl. table 2 Online Resource 1) 
highlighted a significant overrepresentation of the inflammatory pathway 
(pvalueFDR=2.79e-02) represented by the presence of the HLA locus, MAF and TLR4 
genes.
Identification of rare FTLD-TDP genetic risk factors
To identify genes carrying rare FTLD-TDP risk variants we first focused only on genes that 
carried LOF variants. Gene-burden analyses including only these variants did not show 
exome-wide significant association (Online Resource 3) and gene ontology and pathway 
enrichment analyses on all nominally significant genes revealed no particular enrichment in 
biological processes (data not shown). We then focused on 61 genes in which we observed 
LOF variants in at least 3 patients and none in controls. TBK1 showed the most LOF 
mutation carriers (n=7, as discussed above). Prioritization of the remaining 60 genes based 
on similarities with known FTLD-TDP genes using ToppGene identified TRIM21 as the top 
gene based on its functional role within the TBK1-regulated innate immunity pathway (three 
LOF carriers, pvalueToppGene=1.97e-04 after FDR correction, Online Resource 4). Two 
additional genes which are known to function in the same pathway showed significant 
similarity to known FTLD-TDP genes according to ToppGene: IRF-7 (three LOF carriers, 
pvalueToppGene=8.68e-04 after FDR correction) and DHX58 (four LOF carriers, 
pvalueToppGene=1.43e-02 after FDR correction) (Online Resource 5). Interestingly, manual 
inspection of the LOF variants observed in our WGS cohort also revealed one FTLD-TDP 
patient each with LOF variants in IRF8, IRF3 and NOD2 and no LOF variants in controls in 
these genes, further highlighting the importance of the TBK1-regulated innate immunity 
pathway in FTLD-TDP (suppl. figure 2 Online Resource 1). As a second analysis we 
broadened our filtering criteria allowing variants predicted to be pathogenic by two 
prediction algorithms (Polyphen-2 and SIFT) to be added to the LOF variants (Online 
Resource 3). This resulted in one exome-wide significant gene in the burden analysis 
(OSBPL3), however, this association did not remain significant when PCs were excluded 
from the model (pvalue=7.61e-07, pvaluenoPC=2.24e-04). Again, gene ontology and 
pathway analyses on the nominally significant genes failed to detect enrichment in 
biological processes (data not shown). When we selected genes which carried LOF variants 
and coding variants predicted to be pathogenic in at least three patients and no controls, 
similarity analysis with ToppGene ranked NPC1 as the gene most closely resembling known 
FTLD-TDP genes (three variants, pvalueToppGene=6.33e-05 after FDR correction, Online 
Resource 4).
Discussion
The significant heterogeneity in clinical and pathological presentations among FTLD 
patients and the strong correlations between known gene mutations and pathological FTLD 
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subgroups prompted our initiative to establish the international FTLD-TDP whole genome 
sequencing consortium. This allowed us to provide a comprehensive overview of the most 
common known genetic causes of FTLD-TDP and it formed the basis of an unbiased 
genome-wide association study which implicated both common variants at the DPP6, 
UNC13A and HLA-DQA2 genomic loci and rare LOF variants in genes involved in the 
TBK1-immunity pathway in the genetic etiology of FTLD-TDP. The careful pathological 
classification of each patient included in the WGS study into an FTLD-TDP pathological 
subtype, also confirmed rs5848 located in the 3’UTR of GRN as a major risk factor for 
FTLD-TDP, specifically in FTLD-TDP type A.
Focusing on the known genes, combined analysis of 1,151 FTLD-TDP patients across 23 
international sites clearly established the C9orf72 repeat expansion as the most common 
known genetic cause of FTLD-TDP in Caucasian populations, explaining 25.5% of patients. 
We observed a wide range of C9orf72 mutation frequencies across sites (from 10.3% to 
45.5%), which likely reflects the specialized nature of certain clinics and the relative number 
of FTLD-MND patients that are followed. While we carefully excluded known relatives, the 
presence of founder effects may have also inflated the C9orf72 disease frequency in certain 
populations, as suggested elsewhere [87]. Regardless, the high frequency of C9orf72 repeat 
expansions in FTLD-TDP patients underscores the importance of understanding the multiple 
disease mechanisms associated with this mutation such that effective therapies can be 
developed for this significant patient subgroup.[5] Interestingly, in our non-Caucasian 
FTLD-TDP patients, only 10.0% carried a C9orf72 repeat expansion, compared to 20.0% of 
patients with a GRN mutation. While we cannot draw definitive conclusions due to the small 
sample size, GRN mutations thus appear to be the major known genetic cause of FTLD-TDP 
among non-Caucasian populations.
We next focused on the 57.7% of Caucasian FTLD-TDP patients who remained unexplained 
after careful analysis for the presence of pathogenic mutations in known genes. WGS was 
performed on all patients with sufficient DNA quality and quantity available and 517 FTLD-
TDP patients and 838 controls were eventually included in unbiased genetic association 
studies. At the discovery stage, a common variant genome-wide analysis identified the DPP6 
locus at chromosome 7q36 as a novel FTLD-TDP risk locus, with further validation at the 
meta-analysis stage which included 119 additional FTLD-TDP patients and 1,653 controls. 
DPP6 is a type II transmembrane protein exclusively expressed in neurons [13]. It is a 
binding partner of the Kv4-containing A-type K+ channels which are important for 
determining cellular excitability. Based on available studies in mouse and human, one could 
hypothesize that FTLD-TDP associated risk variants reduce the amount of functional DPP6: 
Dpp6 knockout mice show a reduction of hippocampal glutamatergic synapses and impaired 
hippocampus-dependent learning behavior and memory [50,81], DPP6 LOF mutations in 
humans have been associated with neurodevelopmental disorders [48] and autoantibodies 
against DPP6 were found to be the cause of a multifocal neurologic disorder of the central 
and autonomic nervous system [7,34,83]. The identification of two DPP6 LOF mutations in 
our FTLD-TDP patient cohort is further in line with a LOF disease-risk mechanism. 
However, no effect of our top variants (rs4726389 and rs118113626) on brain DPP6 mRNA 
expression levels could be detected, using either publically available data or a custom-
derived frontal cortex RNAseq dataset. Given that these measures were obtained from 
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relatively small numbers of post-mortem tissue samples, using bulk RNAseq, these findings 
do not exclude an effect of these variants on DPP6 expression in (specific) neuronal 
populations. In addition, while our lead SNPs are located in intron 1 of DPP6, we cannot 
rule out an effect on more distantly located genes. It also remains possible that the observed 
risk variants tag a rarer functional variant, only present in a subset of patients, which would 
have hampered our ability to detect an effect. Such functional variant(s) may well be a 
complex rearrangement given that the chromosome 7q36 region is enriched with low copy 
repeats which increase the chance of recombination and chromosomal rearrangements, as 
described [24]. Long-range next-generation sequencing technologies would be needed to test 
this hypothesis in future studies. In fact, in an independent study, paired end and long reads 
Nanopore WGS in a previously unresolved autosomal dominant early-onset dementia family 
linked to 7q36 led to the identification of a large ~4Mb chromosomal inversion disrupting 
DPP6, further implicating loss of DPP6 expression and/or function in early-onset dementia 
(Cacace et al., submitted, 2018). Finally, while the DPP6 locus has been previously 
associated with ALS in some but not all studies [89,15,21,17,28,12,71,91,63], the top ALS-
associated variant (rs10260404) is not in LD with our top SNPs (rs4726389 and rs10260404: 
R2=0.004).
A meta-analysis of the discovery and replication stages revealed two additional genome-
wide significant loci: UNC13A and HLA. The UNC13A locus signal was driven by 
rs12973192 which is in strong LD with rs12608932, a variant associated with ALS [90]. In 
fact, a meta-analysis of ALS and an earlier performed FTLD-TDP GWAS reached genome-
wide association at the UNC13A locus [23], but failed to reach significance in the FTLD-
TDP cohort alone [85,23]. More recently, UNC13A variant rs12608932 was shown to act as 
a phenotypic modifier in ALS patients by increasing the risk for frontotemporal cortical 
atrophy and impaired cognitive performance, reminiscent of an FTLD clinical presentation 
[69]. We also detected a genome-wide significant signal at the HLA locus on chromosome 
6p21.32 led by rs17219281 which is located upstream of the HLA-DQA2 and HLA-DQB2 
genes and has been reported as an eQTL with the rare allele (associated with FTLD-TDP 
risk) robustly increasing the expression of HLA-DQA2 and HLA-DQB2 transcripts in 
several brain regions. Even though most HLA genes are highly polymorphic, the HLA-
DQA2 and HLA-DQB2 genes are poorly polymorphic, yet their biological function has not 
been well characterized [45]. Importantly, the HLA locus has previously been implicated in 
other neurodegenerative disorders including Alzheimer’s and Parkinson’s disease (PD) 
[42,60,33]. Moreover, a large GWAS identified rs9268877 at the HLA-DRA locus on 
6p21.32 as a risk factor for clinical FTLD [26] with subsequent studies emphasizing a 
possible genetic overlap between FTLD and PD through rs9268877 [26,27]. Our FTLD-
TDP associated lead SNP (rs17219281) is not in LD with rs9268877 (R2=0.03) and in 
contrast to our lead SNP, the FTLD and PD-associated risk allele of rs9268877 was 
associated with reduced expression of HLA-DQA2 transcripts [27]. Therefore, even though 
we identified association of FTLD-TDP with a known FTLD risk locus, the specific risk 
variant(s) and the associated disease mechanisms may vary across diseases and give rise to 
distinct neuropathologies. It will likely require the use of dedicated bioinformatic pipelines 
designed to analyze the high complexity of the HLA region to further clarify this issue.
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The requirement of TDP-43 immunohistochemistry and pathological FTLD-TDP subtyping 
for all patients included in the WGS provided a level of quality control in terms of patient 
inclusion above and beyond that of previous studies. It also provided the first opportunity to 
test the hypothesis that different genetic factors influence disease risk in distinct FTLD-TDP 
pathological strata. Excitingly, using only 184 FTLD-TDP type B patients, we identified 
genome-wide significant association with variants in UNC13A, illustrating the power of our 
approach and confirming the overlap between ALS and FTLD-TDP type B in particular. In 
patients with FTLD-TDP type A, a more than 5-fold increased risk was detected for patients 
homozygous for the rare T-allele of rs5848 located in a microRNA binding site within the 
GRN 3’UTR [73] (pvalueREC=4.99e-12; OR=5.16), whereas no risk was observed in FTLD-
TDP type B (pvalueREC=2.04e-2; OR=1.44) and type C (pvalueREC=8.94e-1; OR=1.05) 
patients. Pathological heterogeneity within previously studied patient cohorts (e.g. variable 
proportions of FTLD-TDP type A patients) likely contributed to the discrepant reports on 
the role of rs5848 in FTLD published in the last decade [11,73,75,80]. Importantly, however, 
we previously showed that the r5848 risk allele is associated with reduced GRN expression 
in cerebellar tissue samples to a level intermediate between GRN mutation carriers and 
controls [73] and similar effects of rs5848 on expression were reported in plasma and 
cerebrospinal fluid [36,62]. These findings suggest that reduced GRN levels (resulting from 
rs5848) may contribute to FTLD-TDP type A disease risk in at least a subset of the patients 
without GRN LOF mutations. This would expand the overall contribution of GRN 
dysfunction to FTLD-TDP with likely significant implications once GRN-related therapies 
become available. For FTLD-TDP type C, best known for its lack of a positive family 
history in most patients, we did not identify any genome-wide significant risk factors; 
however, this may have been a result of a lack of power (only 143 FTLD-TDP type C in 
association study).
Finally, our study also sheds new light on TBK1 and the role of the innate immune signaling 
in FTLD. Neuroinflammation and immunity have previously been reported in the context of 
FTLD, and the idea that immune dysfunction may contribute to FTLD risk is not new. 
Microglial activation is a pathological hallmark of patients with FTLD [43,66,82] and a key 
feature of genetic FTLD mouse models [40,52,79,99] and both GRN and C9orf72 have been 
extensively linked to neuroinflammation and microglial activation [41,55,65,99]. Genetic 
overlap between immune-mediated diseases and clinical FTLD was recently reported [8] 
and independent studies found an increased prevalence of autoimmune conditions in patients 
with GRN and C9orf72 mutations, and in clinical FTLD patients predicted to have an 
underlying FTLD-TDP pathology (svPPA and FTLD-MND) [58,59]. In our study, we 
confirmed the importance of TBK1 by establishing it as the third most common genetic 
cause of FTLD-TDP, with LOF variants in 1.5% of Caucasian FTLD-TDP patients. 
Moreover, even though we did not have statistical power to detect exome-wide significant 
association in our rare variant burden analysis, prioritization of genes with an excess of LOF 
variants in FTLD-TDP patients (n≥3) versus controls (n=0) detected several other genes 
involved in the regulation of inflammation and immunity through TBK1 (TRIM21, DHX58, 
IRF7, IRF3, IRF8 and NOD2). Segregation data as well as independent replication is 
necessary to infer a causal or risk effect of such LOF variants. TBK1 encodes a protein 
kinase involved in regulation of the immune response, autophagy and inflammation [35]. In 
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the innate immune signaling pathway, TBK1 can be activated through multiple pathways 
including double stranded (ds)RNA (TLR3-TRIF), lipopolysaccharides (TLR4-TRIF), viral 
RNA (RIG-I-MAVs) and dsDNA (cGAS-STING) resulting in the phosphorylation and 
activation of IRF3/IRF7 (suppl. figure 2 Online Resource 1) [51,47,64]. TBK1 mutations 
observed in ALS and FTLD-TDP patients were previously shown to reduce the activation of 
IRF3 [29,38,84,19], and our observation of LOF variants in IRF3, IRF7 and IRF8 in FTLD-
TDP patients thus points to alternative genetic insults that may have similar consequences. 
TRIM21, with LOF variants in 3 FTLD-TDP patients, also positively regulates innate 
immunity by facilitating the recruitment of TBK1 to MAVS through the regulation of MAVS 
polyubiquitination [98]. DHX58 (mutated in 4 FTLD-TDP patients) was originally thought 
to be a negative regulator of the RIG-I-like receptor family [77,39,100,76]; however, more 
recent work has shown the importance of DHX58 in the enhancement of MDA5-mediated 
antiviral signaling in vivo [78,92]. In fact, studies in Dhx58 knock-out mice found that 
Dhx58 was essential for type I IFN production in response to picornaviridae infection [78]. 
In combination, our findings suggest a critical role for impaired interferon production in 
FTLD-TDP; however, TBK1 is also well known for its role in the autophagy pathway 
through interactions with OPTN and SQSTM1, two other proteins implicated in FTLD-TDP 
etiology [2]. Future studies should therefore decipher the respective roles of IFN signaling 
and autophagy in TBK1-related FTLD-TDP and the possible crosstalk between these two 
pathways [78].
Our study also has some limitations. Since we only recruited 20 non-Caucasian FTLD-TDP 
patients, the GRN and C9orf72 mutation frequencies in this cohort may be unreliable and 
novel gene discovery was not possible. Second, while we included the analyses of both 
common and rare variants, this study only focused on highly selected rare variants and we 
did not analyze copy number and structural variants. Further studies are therefore necessary 
to provide a full overview of the genetic factors contributing to FTLD-TDP. Third, the 
relatively small sample size of our discovery and replication cohorts may have resulted in a 
lack of statistical power to detect weak genetic associations with disease risk. The use of 
clinical FTLD cohorts, enriched for patients with certain clinical FTLD subtypes, may be 
one possible avenue for future replication studies; however, while some genetic risk factors 
will benefit from such approach, some true genetic risk factors may fail to replicate due to 
an increased heterogeneity of underlying pathologies.
In conclusion, our analysis of the largest cohort of pathologically characterized patients with 
FTLD-TDP in which mutations in the known causal genes GRN and C9orf72 were 
excluded, identified three genomic loci harboring common FTLD-TDP risk variants: DPP6, 
UNC13A and HLA-DQA2, and an excess of rare LOF variants in the TBK1-related innate 
immunity pathway in FTLD-TDP patients as compared to controls. Future work will focus 
on the identification of functional variants and their associated disease mechanism at each of 
the associated loci; however, we nominate DPP6 with its modulating effect on K-channel 
activation as a possible novel FTLD-TDP risk gene and we strongly implicate the immune 
pathway in FTLD-TDP pathogenesis.
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Figure 1. Age distributions in each FTLD-TDP pathological subtype
Age at onset, age at death and survival after onset are represented as histogram per FTLD-
TDP pathological subtype. A density curve is superimposed to the histograms.
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Figure 2. Common variant whole genome sequencing association study and DPP6 locus
(a) Manhattan plot of the FTLD-TDP patients versus control association study. The red 
dotted line represents the genome-wide significance level (p=5e-08). (b)Regional 
association (locus zoom) plot of the DPP6 locus. Each dot represents a genotyped variant. 
The purple dot is the most significant variant (rs4726389) among variants in the region. Dots 
are colored from red to blue according to their r2 value, showing their degree of linkage 
disequilibrium with rs4726389 (grey indicates an r2 of zero). The light blue line shows the 
estimated recombination rate. (c) DPP6 mRNA expression levels in function of the 
rs4726389 genotypes without correction for cellular composition in custom RNAseq frontal 
cortex dataset. (d) DPP6 mRNA expression levels in function of the rs4726389 genotypes 
with correction for cellular composition in custom RNAseq frontal cortex dataset. (e) 
Differential DPP6 mRNA expression levels in FTLD-TDP patients and controls without 
correction for cellular composition. (f) Differential DPP6 mRNA expression levels in FTLD-
TDP patients and controls with correction for cellular composition.
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